Canadian pharma firm Valeant will get to takeover North Carolina’s Salix after an improved offer was accepted. Irish firm Endo had made a better offer than Valeant’s original $158 per share, putting the deal at risk. Valeant’s new offer of $173 per share was too rich for Endo to compete with. The deal values Salix at U$15.8 billion including debt.
More market talk: